ng/ml; 6,47±2,92 ng/ml; 5,55±2,97 ng/ml). MMP-3 exhibited highest SF levels in the early OA group (5101,80±9097,81 ng/ml; average OA: 2758,62±6928,32 ng/ml; late OA: 1360,95±1707,99 ng/ml) but showed no correlation with serum levels. MMP-13 reached highest SF concentrations in patients with late OA, similarly TNFalpha. TIMP-1 was not statistically different between the OA groups in SF and revealed increasing levels from the early OA to the late OA group in serum (197,95±41,44 ng/ml; 215,41±40,06 ng/ml; 242,28±42,19 ng/ml) . TIMP-2 level in SF and serum were lowest in the early OA group and revealed a ratio of 1.7:1 to MMP-1 and 1:40,3 to MMP-3. This ratio improved in the later OA groups (TIMP-2:MMP-1: average OA group: 2,86:1; late OA group: 5,16:1; TIMP-2:MMP-3: average OA group: 1:13,99; late OA group: 1:14,21). SF PGE2-concentrations were highest in the early OA group. The CPII:C2C ratio was in the early and the average OA group around the half of that in the late OA group (4,75:1; 3,47:1; 8,24:1); this differences were statistically significant (p > .001). SF levels of C2C and CPII did not correlate with serum levels (r =.349, p =.081; r =.330, p =.108). Histopathology: The early OA group revealed the most intensive inflammatory infiltration, activation of resident cells and activation of synovial stroma (Fig. 2) . The values of all parameters summarized, the early OA group demonstrated an inflammatory grade of 2 by Krenn et al. (moderate synovitis), whereas the synovial tissue in the average OA and the late OA group exhibited slight synovitis (grade 1; Krenn et al.) . Discussion: This study revealed a significant association of the CPII-to-C2C ratio in the synovial fluid with an earlier onset and progression of OA in the knee joint. Furthermore, increased MMP-1 in serum and in the synovial fluid seemed to show a trend to a higher risk of early OA as well as lower ratios of TIMP-2 to MMP-1 and MMP-3. Inflammatory parameters in synovial fluid and synovial tissue appeared increased in the early OA group, indicating a potential contribution of inflammatory mediators to an earlier onset of OA. Clearly, patients at risk for a rapid progression should be at focus of our current and future efforts to modify, i.e., slow or stop, disease progression in OA by more precise diagnostic tools that afford to start treatment when structural alterations are not advanced. 
